Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions

Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 104298 - 104298

Genome-wide association study of leprosy in Malawi and Mali.

Gilchrist JJ. et al, (2022), PLoS pathogens, 18

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.

Datoo MS. et al, (2022), The Lancet. Infectious diseases

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E. et al, (2022), Scientific reports, 12

BIRC6 modifies risk of invasive bacterial infection in Kenyan children.

Gilchrist JJ. et al, (2022), eLife, 11

Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers.

Liu Y-C. et al, (2022), Science (New York, N.Y.), 377, 72 - 79

A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.

Bastard P. et al, (2022), The Journal of experimental medicine, 219

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

Sharpe HR. et al, (2022), JCI Insight, 7

Viral Vectors Expressing Group B Meningococcal Outer Membrane Proteins Induce Strong Antibody Responses but Fail to Induce Functional Bactericidal Activity in Mice.

Marsay L. et al, (2022), The Journal of infection

Virus-like particle vaccines

Mukhopadhyay E. et al, (2022), Vaccinology and Methods in Vaccine Research, 163 - 176

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Paths and timings of the peopling of Polynesia inferred from genomic networks.

Ioannidis AG. et al, (2021), Nature, 597, 522 - 526

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

McAuliffe J. et al, (2021), Journal for immunotherapy of cancer, 9

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?